SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (798)3/30/1998 12:04:00 PM
From: Carl Wysocki  Respond to of 1029
 
Nah, his replacement will just initiate coverage with a buy rating
and add it back to the recommended list.

Besides the old analyst can now accumulate for his own firm.

Carl



To: Robohogs who wrote (798)3/30/1998 2:18:00 PM
From: IRWIN JAMES FRANKEL  Read Replies (2) | Respond to of 1029
 
I don't think GS will drop coverage of ICN but will transfer it to another analyst. They had been promising coverage to ICN for years when the market cap and company prospects justified.

It would also be a great disservice to their customers.

My guess: They will maintain coverage.

Time will tell.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News